Parliamentary Search

Written question asked by Anne Milton (Conservative) on Monday, 8 March 2010, in the House of Commons. It was due for an answer on Wednesday, 10 March 2010. It was answered by Mike O'Brien (Labour) on Friday, 12 March 2010 on behalf of the Department of Health.

Cancer: Drugs

Question
To ask the Secretary of State for Health what drugs for the treatment of cancer the National Institute for Health and Clinical Excellence has (a) recommended and (b) not recommended for NHS use since 1 November 2008; how long the appraisal of each took; and whether the pharmaceutical company supplying each such drug offered to make it available on a risk-sharing basis.
Answer

The information requested is shown in the table. For each of the appraisals, the table shows whether one or more Patient Access Schemes agreed between the Department of Health and the manufacturer have been considered by the National Institute for Health and Clinical Excellence (NICE).

Topic Start of NICE appraisal¹ Date of final NICE guidance Recommendation Patient access scheme considered by NICE
Yondelis (trabectedin) for soft tissue sarcoma September 2008 February 2010 Partial recommendation Yes
Hycamtin (topotecan) for small cell lung cancer August 2008 November 2009 Partial recommendation No
Hycamtin (topotecan) for Cervical Cancer (recurrent) December 2008 October 2009 Partial recommendation No
Sutent (sunitinib) for Gastrointestinal stromal tumours August 2008 September 2009 Partial recommendation Yes
Alimta (pemetrexed) for the first-line treatment of non- small-cell lung cancer October 2008 September 2009 Partial recommendation No
Erbitux (cetuximab) for Colorectal Cancer (first line) January 2008 August 2009 Partial recommendation Yes
Avastin (bevacizumab) (first-line), Nexavar (sorafenib) (first-line and second-line), Sutent (sunitinib) (second-line) and Torisel (temsirolimus) (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma September 2007² August 2009 Not recommended Nexavar (sorafenib) - yes
Avastin (bevacizumab )-yes
Sutent (sunitinib) - yes
Mabthera (rituximab) for first-line treatment of chronic lymphocytic leukaemia September 2008 July 2009 Partial recommendation No
Erbitux (cetuximab) for Head and Neck Cancer (squamous cell carcinoma) September 2008 June 2009 Not Recommended No
Revlimid (lenalidomide) for Multiple Myeloma April 2008 June 2009 Partial recommendation Yes
Sutent (sunitinib) for the first-line treatment of advanced and/or metastatic renal cell carcinoma September 2007² March 2009 Partial recommendation Yes
Tarceva (erlotinib) for the treatment of non- small-cell lung cancer March 2006 November 2008 Partial recommendation Yes
¹ The date NICE commenced work on the appraisal. NICE will also have carried out scoping work for the appraisal before this date.
² This is the date on which the Multiple Technology Appraisal (MTA) began for Avastin (bevacizumab) (first-line), Nexavar (sorafenib) (first-line and second-line), Sutent (sunitinib) (first and second-line) and Torisel (temsirolimus) (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma. The MTA was subsequently split and Sutent (sunitinib) for the first-line treatment of renal cell carcinoma was considered in a separate single technology appraisal.

Secondary information

Type
Written question
Reference
507 c563-6W; 321547
Session
2009-10
Subjects
Cancer Drugs
Link
View this Written question on www.publications.parliament.uk